{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:45:06Z","timestamp":1785545106401,"version":"3.56.0"},"reference-count":26,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Public Health Surveill"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Digital adherence technologies (DATs) are promising tools for supporting tuberculosis (TB) treatment. DATs can serve as reminders for people with TB to take their medication and act as proxies for adherence monitoring. Strong engagement with DATs, from both the person with TB and health care provider (HCP) perspectives, is essential for ensuring intervention fidelity. The Adherence Support Coalition to End TB (ASCENT) project evaluated 2 types of DATs, pillboxes and medication labels (99DOTS), in cluster-randomized trials across 5 countries.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aims to investigate participant and HCP engagement with DATs for TB treatment, stratified by DAT type and country.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This study is a subanalysis of data generated through the ASCENT trials, which enrolled adults with drug-susceptible TB. A digital dose was defined as either a pillbox opening (for pillbox users) or a dosing confirmation SMS text message sent by the participant (for label users), both of which were recorded on the adherence platform. Descriptive analysis was used to provide an overview of dose-day outcomes. DAT engagement was assessed from both participant and HCP perspectives. To enhance participant engagement, we summarized the frequency of digital engagement overall and by treatment phase, as well as the frequency of consecutive days without engagement. For HCP engagement, we summarized the frequency of doses added manually, the number of days between the actual dose day and when a manual dose was added, and instances of consecutive manual dosing lasting more than 3 and more than 7 days, where doses were added more than 1 week after the dose day.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of the 9511 participants included, 6719 (70.64%) were using the pillbox, 3544 (37.26%) were female, and the median age was 40 years. Across DAT types, there were 1,384,879 dose days, with 973,876 (70.32%) contributed by pillbox users. Of all dose days, 1,165,195 (84.14%) were recorded as digital, 156,664 (11.31%) as manual, 59,045 (4.26%) had no information, and 3975 (0.29%) were confirmed as missed. Digital dosing decreased slightly from the intensive to the continuation phase. The percentage of digital dose days was higher among pillbox users (851,496\/973,876, 87.43%) compared with label users (313,699\/411,003, 76.33%). Among label users, manual dosing was most common in the Philippines (37,919\/171,786, 22.07%) and least common in Tanzania (11,108\/76,231, 14.57%). Among pillbox users, manual dosing was most common in the Philippines (24,015\/208,130, 11.54%) and Ukraine (13,209\/111,901, 11.80%). Overall, 512 out of 2792 (18.34%) label users and 588 out of 6719 (8.75%) pillbox users experienced a run of more than 7 consecutive nondigital dose days that were resolved more than 1 week after the dose day. The highest occurrence was observed in the Philippines (368\/1142, 32.22%, for label users and 224\/1351, 16.58%, for pillbox users).<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n There was considerable variation in DAT engagement across countries and DAT types, reflecting differences in how the intervention was implemented. Further refinement of the intervention and improvements in its delivery may be necessary to enhance outcomes.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/62881","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:10:07Z","timestamp":1749168607000},"page":"e62881-e62881","source":"Crossref","is-referenced-by-count":1,"title":["Engagement With Digital Adherence Technologies as Measures of Intervention Fidelity Among Adults With Drug-Susceptible Tuberculosis and Health Care Providers: Descriptive Analysis Using Data From Cluster-Randomized Trials in Five Countries"],"prefix":"10.2196","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-3947","authenticated-orcid":false,"given":"Jason","family":"Alacapa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7805-3191","authenticated-orcid":false,"given":"Amare Worku","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0768-4877","authenticated-orcid":false,"given":"Natasha","family":"Deyanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3928-7574","authenticated-orcid":false,"given":"Tanyaradzwa","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7664-8354","authenticated-orcid":false,"given":"Andrew","family":"Mganga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5930-7162","authenticated-orcid":false,"given":"Rachel","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5898-6306","authenticated-orcid":false,"given":"Job","family":"van Rest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7667-2108","authenticated-orcid":false,"given":"Norma","family":"Madden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4723-5955","authenticated-orcid":false,"given":"Egwuma","family":"Efo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7143-1009","authenticated-orcid":false,"given":"Salome","family":"Charalambous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2526-1708","authenticated-orcid":false,"given":"Kristian","family":"van Kalmthout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7853-4211","authenticated-orcid":false,"given":"Degu","family":"Jerene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6524-3754","authenticated-orcid":false,"given":"Katherine","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"R1","unstructured":"Global tuberculosis report 2024. World Health Organization (WHO). 2024. URL: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024 [Accessed 08-07-2025]"},{"key":"R2","unstructured":"Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. World Health Organization (WHO). 2017. URL: https:\/\/iris.who.int\/bitstream\/handle\/10665\/255052\/9789241550000-eng.pdf [Accessed 08-07-2025]"},{"issue":"22","key":"R3","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1001\/jama.293.22.2767","article-title":"Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally","volume":"293","author":"Dye","journal-title":"JAMA"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Mohamed MS Zary M Kafie C et al. The impact of digital adherence technologies on health outcomes in tuberculosis: a systematic review and meta-analysis. medRxiv. Preprint posted online on Feb 3, 2024. [doi: 10.1101\/2024.01.31.24302115]","DOI":"10.1101\/2024.01.31.24302115"},{"issue":"2","key":"R5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2024-016608","article-title":"Contextual factors influencing implementation of tuberculosis digital adherence technologies: a scoping review guided by the RE-AIM framework","volume":"10","author":"Bahukudumbi","journal-title":"BMJ Glob Health"},{"issue":"2","key":"R6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2024-016535","article-title":"Implementation outcomes of tuberculosis digital adherence technologies: a scoping review using the RE-AIM framework","volume":"10","author":"Chilala","journal-title":"BMJ Glob Health"},{"issue":"5","key":"R7","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed7050065","article-title":"Time trend analysis of tuberculosis treatment while using digital adherence technologies-an individual patient data meta-analysis of eleven projects across ten high tuberculosis-burden countries","volume":"7","author":"de Groot","journal-title":"Trop Med Infect Dis"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Tadesse AW Sahile M Foster N et al. Cluster-randomized trial of digital adherence technologies and differentiated care to reduce poor end-of-treatment outcomes and recurrence among adults with drug-sensitive pulmonary TB in ethiopia. medRxiv. Preprint posted online on May 9, 2024. [doi: 10.1101\/2024.05.09.24307117]","DOI":"10.1101\/2024.05.09.24307117"},{"issue":"10485","key":"R9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(24)02847-2","article-title":"Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials","volume":"405","author":"Jerene","journal-title":"Lancet"},{"key":"R10","unstructured":"99DOTS deployments. 99DOTS. URL: https:\/\/www.99dots.org\/ [Accessed 07-07-2025]"},{"issue":"3","key":"R11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068685","article-title":"Effectiveness of digital adherence technologies in improving tuberculosis treatment outcomes in four countries: a pragmatic cluster randomised trial protocol","volume":"13","author":"Jerene","journal-title":"BMJ Open"},{"issue":"1","key":"R12","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06833-x","article-title":"Evaluation of implementation and effectiveness of digital adherence technology with differentiated care to support tuberculosis treatment adherence and improve treatment outcomes in Ethiopia: a study protocol for a cluster randomised trial","volume":"21","author":"Tadesse","journal-title":"BMC Infect Dis"},{"issue":"3","key":"R13","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed10030068","article-title":"Process evaluation of pragmatic cluster-randomized trials of digital adherence technologies for tuberculosis treatment support: a mixed-method study in five countries","volume":"10","author":"Madden","journal-title":"Trop Med Infect Dis"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1327971","article-title":"Feasibility and acceptability of the smart pillbox and medication label with differentiated care to support person-centered tuberculosis care among ASCENT trial participants - a multicountry study","volume":"12","author":"Tadesse","journal-title":"Front Public Health"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.2196\/54117","article-title":"Digital adherence technologies and differentiated care for tuberculosis treatment and their acceptability among persons with tuberculosis, health care workers, and key informants in the Philippines: qualitative interview study","volume":"11","author":"Leung","journal-title":"JMIR Hum Factors"},{"key":"R16","volume":"26","author":"Deyanova","journal-title":"The International Journal of Tuberculosis and Lung Disease (IJTLD)"},{"issue":"1","key":"R17","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7892-9","article-title":"Requiring smartphone ownership for mHealth interventions: who could be left out?","volume":"20","author":"Bommakanti","journal-title":"BMC Public Health"},{"issue":"1","key":"R18","doi-asserted-by":"publisher","DOI":"10.2196\/21244","article-title":"Mobile phone access and implications for digital health interventions among adolescents and young adults in Zimbabwe: cross-sectional survey","volume":"9","author":"Doyle","journal-title":"JMIR Mhealth Uhealth"},{"issue":"3","key":"R19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065202","article-title":"Qualitative study exploring the feasibility of using medication monitors and a differentiated care approach to support adherence among people receiving TB treatment in South Africa","volume":"13","author":"Mukora","journal-title":"BMJ Open"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Zary M Mohamed MS Kafie C et al. The performance of digital technologies for measuring tuberculosis medication adherence: a systematic review. 2024;9(7):e015633.","DOI":"10.1136\/bmjgh-2024-015633"},{"issue":"6","key":"R21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pdig.0000138","article-title":"Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB in Uganda","volume":"2","author":"Kiwanuka","journal-title":"PLOS Digit Health"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102745","article-title":"Treatment adherence and clinical outcomes amongst in people with drug-susceptible tuberculosis using medication monitor and differentiated care approach compared with standard of care in South Africa: a cluster randomized trial","volume":"75","author":"Charalambous","journal-title":"EClinicalMedicine"},{"issue":"5","key":"R23","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1016\/S2214-109X(23)00068-2","article-title":"Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial","volume":"11","author":"Liu","journal-title":"Lancet Glob Health"},{"issue":"4","key":"R24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.5588\/ijtld.22.0500","article-title":"The effect of medication event reminder monitoring on treatment adherence of TB patients","volume":"27","author":"Velen","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10430","key":"R25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(23)02270-5","article-title":"Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial","volume":"403","author":"Wei","journal-title":"Lancet"},{"key":"R26","unstructured":"Data for: \u201cengagement with digital adherence technologies among adults with drug-susceptible tuberculosis: data from cluster randomized trials in five countries\u201d \u2013 data codebook. LSHTM Data Compass. URL: https:\/\/datacompass.lshtm.ac.uk\/id\/eprint\/4695\/3\/Participant_doseday_data_codebook.html [Accessed 07-07-2025]"}],"container-title":["JMIR Public Health and Surveillance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publichealth.jmir.org\/2025\/1\/e62881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:31:25Z","timestamp":1785537085000},"score":1,"resource":{"primary":{"URL":"https:\/\/publichealth.jmir.org\/2025\/1\/e62881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":26,"URL":"https:\/\/doi.org\/10.2196\/62881","relation":{},"ISSN":["2369-2960"],"issn-type":[{"value":"2369-2960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"article-number":"v11i22e62881"}}